| Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries | Ca-A Cancer Journal for Clinicians | 2021 | 11.2K |
| Cancer Statistics, 2021 | Ca-A Cancer Journal for Clinicians | 2021 | 4K |
| Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia | Blood | 2021 | 274 |
| Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 | Journal of Thrombosis and Thrombolysis | 2021 | 254 |
| Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination | American Journal of Hematology | 2021 | 183 |
| American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 | Blood Advances | 2021 | 161 |
| High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types | Annals of Oncology | 2021 | 158 |
| Current treatment and recent progress in gastric cancer | Ca-A Cancer Journal for Clinicians | 2021 | 121 |
| CAR-T cell therapy: current limitations and potential strategies | Blood Cancer Journal | 2021 | 119 |
| Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study | Lancet Haematology,the | 2021 | 105 |
| Exosome-based liquid biopsies in cancer: opportunities and challenges | Annals of Oncology | 2021 | 105 |
| COVID-19-associated coagulopathy and disseminated intravascular coagulation | International Journal of Hematology | 2021 | 102 |
| Neutrophil extracellular traps and thrombosis in COVID-19 | Journal of Thrombosis and Thrombolysis | 2021 | 99 |
| Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH | Hamostaseologie | 2021 | 97 |
| American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer | Blood Advances | 2021 | 96 |
| A neutrophil activation signature predicts critical illness and mortality in COVID-19 | Blood Advances | 2021 | 93 |
| Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study | Lancet Haematology,the | 2021 | 93 |
| Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes | Blood Reviews | 2021 | 92 |
| Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2021 | 92 |
| Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution | Journal of Hematology and Oncology | 2021 | 87 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer | Annals of Oncology | 2021 | 87 |
| Antibody-induced procoagulant platelets in severe COVID-19 infection | Blood | 2021 | 86 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium | Annals of Oncology | 2021 | 85 |
| Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose | Blood | 2021 | 80 |
| Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma | Lancet Haematology,the | 2021 | 80 |
